HYPE: 'taurine deficiency drives human aging' — the headline outran the human evidence
A 2023 Science paper (Singh et al.) reported taurine declines with age across species and that supplementation extended healthspan in animals, proposing taurine deficiency as "a driver of aging" — and a supplement wave followed. A 2025 Aging Cell study of 137 men aged 20-93 found no association between circulating taurine and age, muscle, performance, or mitochondrial function (PMID 41061678). Tracked as a contrarian indicator: loud cross-species biology, thin human proof.
This card exists on purpose (LD-03). The original finding is real science — Vijay K. Yadav et al. (Science, 9 Jun 2023; DOI 10.1126/science.abn9257) showed taurine declines with age in mice, monkeys and humans and that supplementation extended healthspan (and lifespan in mice/worms). But the human anti-aging / biomarker narrative ran far ahead of the evidence.
The contrarian receipt: a 2025 Aging Cell study (Vincent Marcangeli, Gilles Gouspillou, UQAM; credited) of 137 men aged 20-93 found no association between circulating taurine and age, muscle mass, strength, physical performance or mitochondrial function — directly challenging taurine deficiency as a primary driver of human aging.
Why hype, not signal: the loud claim ("taurine reverses aging in humans / use it as a biomarker") lacks supporting human primary evidence and is now contradicted. The underlying animal biology remains a legitimate research signal.
Falsifier: a powered human RCT showing reproducible benefit. · Confidence: 0.85 that the strong human claim is currently unsupported.
So we should keep taurine off the verified shelf, watch the human RCTs, and use this as a template for the hype-vs-verified ledger.
Do not treat blood taurine as an aging biomarker or taurine pills as a longevity intervention; flag consumer products making the claim as evidence-ahead-of-data.
domains: longevity · supplements · biomarkers · contrarian · hype